Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Free Report) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 21,300 shares, an increase of 76.0% from the August 15th total of 12,100 shares. Based on an average daily volume of 50,600 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the shares of the stock are short sold.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Connect Biopharma in a research report on Friday, September 6th.
Read Our Latest Analysis on CNTB
Hedge Funds Weigh In On Connect Biopharma
Connect Biopharma Stock Performance
Shares of CNTB traded up $0.03 during trading hours on Friday, hitting $1.23. The stock had a trading volume of 8,772 shares, compared to its average volume of 95,628. The firm has a 50 day simple moving average of $1.21 and a 200-day simple moving average of $1.42. Connect Biopharma has a 1-year low of $0.53 and a 1-year high of $2.84.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
See Also
- Five stocks we like better than Connect Biopharma
- Investing in Construction Stocks
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- How to Capture the Benefits of Dividend Increases
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.